Description: XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.
Home Page: www.xortx.com
XRTX Technical Analysis
421 – 7th Avenue SW
Vancouver,
BC
T2P 4K9
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, Pres & Director |
| Mr. Amar Keshri C.A., CPA | Chief Financial Officer |
| Nick Rigopoulos | Director of Communications |
| Dr. David Sans M.B.A., Ph.D. | Director of Corp. Devel. |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations |
| Dr. Stacy Evans M.B.A., M.D. | Chief Bus. Officer |
| Ms. Charlotte May | Corp. Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0.9621 |
|---|---|
| Trailing PE: | 2.1131 |
| Price-to-Book MRQ: | 1.4851 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-11-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |